WO2024087521A1 - Anticorps anti-cd3 et son application - Google Patents

Anticorps anti-cd3 et son application Download PDF

Info

Publication number
WO2024087521A1
WO2024087521A1 PCT/CN2023/086578 CN2023086578W WO2024087521A1 WO 2024087521 A1 WO2024087521 A1 WO 2024087521A1 CN 2023086578 W CN2023086578 W CN 2023086578W WO 2024087521 A1 WO2024087521 A1 WO 2024087521A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cancer
bcma
seq
antigen
Prior art date
Application number
PCT/CN2023/086578
Other languages
English (en)
Chinese (zh)
Inventor
成赢
曹国帅
李洋洋
武玉伟
Original Assignee
合肥天港免疫药物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 合肥天港免疫药物有限公司 filed Critical 合肥天港免疫药物有限公司
Publication of WO2024087521A1 publication Critical patent/WO2024087521A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to the field of biomedicine, and in particular to an anti-CD3 antibody and application thereof.
  • T lymphocytes play a very important role in the adaptive immune response and the precise regulation of the immune response.
  • the T cell receptor (TCR) on the surface of T cells exists in the form of heterodimers of ⁇ and ⁇ or ⁇ and ⁇ . After receiving the antigen peptide signal from the antigen presenting cell, the TCR cannot directly mediate the intracellular signal, but needs to form a complex with the CD3 molecule. Not only ⁇ and ⁇ TCRs form a complex with CD3, but ⁇ and ⁇ TCRs also form a complex with CD3. The loss of TCR or CD3 genes can lead to the disappearance of the TCR-CD3 complex from the surface of T cells.
  • the CD3 molecule is composed of 3 pairs of peptide chains formed by 5 peptide chains.
  • CD3 90% of CD3 is composed of ⁇ , ⁇ and ⁇ , while the other 10% of CD3 is composed of ⁇ , ⁇ and ⁇ .
  • the immunoreceptor tyrosine activation motif in the intracellular region of each CD3 peptide chain is phosphorylated by the tyrosine protein kinase p56 in the T cell, recruits and binds to tyrosine kinases such as ZAP-70, and participates in mediating TCR activation signals.
  • bispecific antibodies based on T cell redirection
  • the target of CD3 is widely selected.
  • CD3-related bispecific antibodies can mediate T cell activation by bypassing TCR and peptide-major histocompatibility complex (pMHC), but the molecular process in the synapse is very similar to the interaction of classical TCR-pMHC.
  • the activity of bispecific antibodies is affected by CD3 affinity.
  • CD3 high-affinity bispecific antibodies have better promoting killing effects in in vitro experiments, but there is a higher risk of release factor syndrome in vivo.
  • studies have found that very low-affinity CD3 antibody sequences can also effectively stimulate T cell activation after constructing bispecific antibodies.
  • the bispecific antibody will prompt T cells to selectively locate to the tumor rather than in the peripheral circulation, avoiding systemic activation.
  • CD3 antibodies are species-specific. For example, clones such as UCHT-1, OKT3, and L2K react only with chimpanzee CD3 but not with other primates such as cynomolgus monkeys and rhesus monkeys CD3 or mouse CD3. Since new drug development must undergo rigorous non-clinical trials before clinical research can be conducted, it is necessary to find relevant species for preclinical safety evaluation. The use of chimpanzees for drug safety testing is highly restricted. Among the currently known CD3 antibodies with human-monkey cross-reactivity, the affinity of the SP34 antibody decreases by an order of magnitude after forming a single-chain antibody.
  • the inventors of the present application have successfully screened a mouse anti-CD3 monoclonal antibody that has high binding activity to human or monkey CD3 protein.
  • the inventors partially humanized the constant region of the obtained mouse antibody and retained the CDR of the mouse anti-CD3 monoclonal antibody to obtain a chimeric antibody.
  • the framework region in the light chain variable region or the heavy chain variable region of the chimeric antibody was humanized to obtain a fully humanized anti-CD3 antibody.
  • the chimeric antibody and humanized antibody can not only specifically target and bind to human CD3 protein and monkey CD3 protein, but also have the characteristics of low immunogenicity, and can effectively treat and/or prevent CD3-mediated related diseases, such as autoimmune diseases.
  • the bispecific antibody (bispecific antibody) or multispecific antibody (multispecific antibody) prepared using the anti-CD3 antibody can also specifically target and bind to human CD3 protein and monkey CD3 protein, and generally, based on the specificity of the bispecific antibody or multispecific antibody, the bispecific antibody or multispecific antibody can target T cells to other antigens, eliminate cells producing such antigens through T cell-mediated cell killing, thereby treating various diseases, such as tumors.
  • the present invention proposes an antibody or antigen-binding fragment.
  • it comprises a CDR sequence selected from at least one of the following or an amino acid sequence having at least 95% identity therewith: heavy chain variable region CDR sequence: SEQ ID NO: 1-3, light chain variable region CDR sequence: SEQ ID NO: 4-6.
  • the antibody or antigen-binding fragment according to the embodiment of the present invention can bind to human or monkey CD3 protein and effectively treat or prevent CD3-mediated related diseases.
  • the above-mentioned antibody or antigen-binding fragment may further include at least one of the following additional technical features:
  • the antibody or antigen-binding fragment comprises: heavy chain variable region CDR1, CDR2, CDR3 sequences as shown in SEQ ID NO: 1, 2 and 3, or an amino acid sequence with at least 95% identity to SEQ ID NO: 1, 2 and 3; and/or light chain variable region CDR1, CDR2, CDR3 sequences as shown in SEQ ID NO: 4, 5 and 6, or an amino acid sequence with at least 95% identity to 4, 5 and 6.
  • the antibody or antigen-binding fragment comprises: a heavy chain variable region CDR1 sequence as shown in SEQ ID NO: 1, as shown in SEQ ID NO: 2, the heavy chain variable region CDR2 as shown in SEQ ID NO: 3, the light chain variable region CDR1 as shown in SEQ ID NO: 4, the light chain variable region CDR2 as shown in SEQ ID NO: 5, and the light chain variable region CDR3 as shown in SEQ ID NO: 6.
  • the antibody or antigen-binding fragment comprises: at least one of a heavy chain FR region and a light chain FR region.
  • At least a portion of at least one of the heavy chain FR region and the light chain FR region is derived from at least one of a human antibody, a primate antibody, a murine antibody, or a mutant thereof.
  • the antibody or antigen-binding fragment comprises: at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences shown in SEQ ID NO: 7 to 10, respectively; or at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences shown in SEQ ID NO: 15 to 18, respectively.
  • the antibody or antigen-binding fragment comprises: at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences shown in SEQ ID NO: 11 to 14, respectively; or at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences shown in SEQ ID NO: 19 to 22, respectively.
  • the antibody or antigen-binding fragment comprises: at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences as shown in SEQ ID NO: 7 to 10, respectively; at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences as shown in SEQ ID NO: 11 to 14, respectively; or at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences as shown in SEQ ID NO: 15 to 18, respectively; at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences as shown in SEQ ID NO: 19 to 22, respectively.
  • the antibody or antigen-binding fragment includes: a heavy chain variable region as shown in SEQ ID NO: 23 or SEQ ID NO: 27; and/or a light chain variable region as shown in SEQ ID NO: 24 or SEQ ID NO: 28.
  • the antibody or antigen-binding fragment includes: 1) a heavy chain variable region as shown in SEQ ID NO:23, and a light chain variable region as shown in SEQ ID NO:24; or 2) a heavy chain variable region as shown in SEQ ID NO:27, and a light chain variable region as shown in SEQ ID NO:28.
  • the antibody or antigen-binding fragment contains at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a human antibody, a primate antibody and a murine antibody or a mutant thereof.
  • the light chain constant region and the heavy chain constant region are both derived from a murine IgG antibody or a mutant thereof or a human IgG antibody or a mutant thereof.
  • the light chain constant region and the heavy chain constant region are both derived from a murine IgG1 antibody or a mutant thereof or a human IgG1 antibody or a mutant thereof.
  • the antibody has a heavy chain constant region with an amino acid sequence as shown in SEQ ID NO: 29 or 33 and/or a light chain constant region with an amino acid sequence as shown in SEQ ID NO: 30 or 34.
  • the antibody or antigen-binding fragment has a heavy chain having an amino acid sequence shown in any one of SEQ ID NO: 35, 37 and 39, and a light chain having an amino acid sequence shown in any one of SEQ ID NO: 36, 38 and 40.
  • the antibody or antigen-binding fragment has a heavy chain with an amino acid sequence shown in SEQ ID NO:35 and a light chain with an amino acid sequence shown in SEQ ID NO:36; the antibody or antigen-binding fragment has a heavy chain with an amino acid sequence shown in SEQ ID NO:37 and a light chain with an amino acid sequence shown in SEQ ID NO:38; or the antibody or antigen-binding fragment has a heavy chain with an amino acid sequence shown in SEQ ID NO:39 and a light chain with an amino acid sequence shown in SEQ ID NO:40.
  • the antibody or antigen-binding fragment comprises a monoclonal antibody or a polyclonal antibody.
  • the monoclonal antibody includes at least one of a full-length antibody, Fv, a single-chain antibody, Fab, a single-domain antibody and a minimum recognition unit.
  • the present invention proposes a bispecific antibody.
  • it includes a first binding region, the first binding region comprises the antibody or antigen-binding fragment described in the first aspect; and a second binding region, the second binding region has BCMA or B7H6 binding activity.
  • the bispecific antibody according to an embodiment of the present invention can bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, and can be applied to scientific research, or effectively treat or prevent CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the binding activity of the second binding region is not particularly limited and may have other binding activities, as long as the bispecific antibody has the antibody or antigen-binding fragment described in the first aspect, and the antibody or antigen-binding fragment and the second binding region can both effectively function.
  • the antibodies or antigen-binding fragments described in the present application can also be used to prepare more specific antibodies, such as trispecific, tetraspecific, and pentaspecific. Based on the multispecificity of the antibody, the antibody or antigen-binding fragment of the present invention can target T cells to other antigens and eliminate cells that produce such antigens through T cell-mediated cell killing.
  • the above-mentioned bispecific antibody may further include at least one of the following additional technical features:
  • the bispecific antibody comprises a symmetric bispecific antibody or an asymmetric bispecific antibody.
  • the dual antibody is a symmetrical dual antibody.
  • the antibody or antigen-binding fragment is an anti-CD3 single-chain antibody.
  • the second binding region includes at least one of a full-length antibody, Fv, single-chain antibody, Fab, single-domain antibody and a minimum recognition unit having BCMA or B7H6 binding activity.
  • the specific composition of the second binding region is not particularly limited, as long as it has BCMA or B7H6 binding activity, and can be a complete full-length antibody or an antibody fragment (antigen binding fragment).
  • the second binding region comprises an anti-BCMA single-chain antibody or an anti-B7H6 single-chain antibody.
  • the anti-CD3 single-chain antibody comprises an anti-CD3 antibody light chain variable region and an anti-CD3 antibody heavy chain variable region
  • the anti-CD3 antibody heavy chain variable region has the amino acid sequence shown in SEQ ID NO: 23 or 27
  • the anti-CD3 antibody light chain variable region has the amino acid sequence shown in SEQ ID NO: 24 or 28.
  • the anti-CD3 single-chain antibody further includes a connecting peptide 1, wherein the N-terminus of the connecting peptide 1 is connected to the C-terminus of the heavy chain variable region of the anti-CD3 antibody, and the C-terminus of the connecting peptide 1 is connected to the N-terminus of the light chain variable region of the anti-CD3 antibody; or the N-terminus of the connecting peptide 1 is connected to the C-terminus of the light chain variable region of the anti-CD3 antibody, and the C-terminus of the connecting peptide 1 is connected to the N-terminus of the heavy chain variable region of the anti-CD3 antibody.
  • the anti-BCMA single-chain antibody comprises an anti-BCMA antibody light chain variable region and an anti-BCMA antibody heavy chain variable region
  • the anti-BCMA antibody light chain variable region has the amino acid sequence shown in SEQ ID NO:42
  • the anti-BCMA antibody heavy chain variable region has the amino acid sequence shown in SEQ ID NO:61.
  • the anti-BCMA single-chain antibody further includes a connecting peptide 2, wherein the N-terminus of the connecting peptide 2 is connected to the C-terminus of the anti-BCMA antibody heavy chain variable region, and the C-terminus of the connecting peptide 2 is connected to the N-terminus of the anti-BCMA antibody light chain variable region; or the N-terminus of the connecting peptide 2 is connected to the C-terminus of the anti-BCMA antibody light chain variable region, and the C-terminus of the connecting peptide 2 is connected to the N-terminus of the anti-BCMA antibody heavy chain variable region.
  • the anti-B7H6 single-chain antibody comprises an anti-B7H6 antibody light chain variable region and an anti-B7H6 antibody heavy chain variable region
  • the anti-B7H6 antibody heavy chain variable region has the amino acid sequence shown in SEQ ID NO:63
  • the anti-B7H6 antibody light chain variable region has the amino acid sequence shown in SEQ ID NO:62.
  • the anti-B7H6 single-chain antibody further includes a connecting peptide 3, wherein the N-terminus of the connecting peptide 3 is connected to the C-terminus of the heavy chain variable region of the anti-B7H6 antibody, and the C-terminus of the connecting peptide 3 is connected to the N-terminus of the light chain variable region of the anti-B7H6 antibody; or the N-terminus of the connecting peptide 3 is connected to the C-terminus of the light chain variable region of the anti-B7H6 antibody, and the C-terminus of the connecting peptide 3 is connected to the N-terminus of the heavy chain variable region of the anti-B7H6 antibody.
  • the connecting peptide 1 has an amino acid sequence (GGS)n, wherein n is an integer greater than or equal to 1, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • At least one of the connecting peptide 2 and the connecting peptide 3 has an amino acid sequence (GGGGS)n, wherein n is an integer greater than or equal to 1, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • connecting peptides 1, 2, and 3 described herein are not particularly limited, and any conventional connecting peptides in the art can be used, such as conventional flexible amino acid fragments or rigid amino acid fragments.
  • the connecting peptide 1 has the amino acid sequence shown in SEQ ID NO:48.
  • the connecting peptides 2 and 3 have the amino acid sequence shown in SEQ ID NO:41.
  • the anti-CD3 single-chain antibody has an amino acid sequence as shown in SEQ ID NO:45.
  • the anti-BCMA single-chain antibody has an amino acid sequence as shown in SEQ ID NO:46.
  • the anti-B7H6 single-chain antibody has an amino acid sequence as shown in SEQ ID NO:47.
  • the first antigen binding region further includes a first Fc peptide segment, and the N-terminus of the first Fc peptide segment is connected to the C-terminus of the antibody or antigen binding fragment.
  • the second antigen binding region further includes a second Fc peptide segment, and the N-terminus of the second Fc peptide segment is connected to the C-terminus of the anti-BCMA single-chain antibody or the anti-B7H6 single-chain antibody.
  • the first Fc peptide segment has the amino acid sequence shown in SEQ ID NO:49.
  • the second Fc peptide segment has the amino acid sequence shown in SEQ ID NO:50.
  • the first Fc peptide segment and the second Fc peptide segment are connected via a knob-into-hole structure.
  • the amino acid sequences of the first Fc peptide segment and the second Fc peptide segment may be the same or different, for example, when they have the same amino acid sequence, the first Fc peptide segment and the second Fc peptide segment may be connected via a disulfide bond.
  • the first antigen binding region has the amino acid sequence shown in SEQ ID NO:51
  • the second antigen binding region has the amino acid sequence shown in SEQ ID NO:52 or 53.
  • nucleic acid encoding the antibody or antigen-binding fragment thereof or the bispecific antibody of the present invention is within the scope of the present invention. Based on its amino acid sequence, a person skilled in the art can easily obtain the corresponding nucleic acid sequence.
  • the present invention provides a nucleic acid molecule encoding the antibody or antigen-binding fragment or the bispecific antibody described in the first aspect.
  • the antibody or antigen-binding fragment encoded by the nucleic acid molecule can bind to human or monkey CD3 protein, effectively treat or prevent CD3-mediated related diseases
  • the bispecific antibody encoded by the nucleic acid molecule can bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, effectively treat or prevent CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the above nucleic acid molecule may further include at least one of the following additional technical features:
  • the nucleic acid molecule is DNA.
  • nucleic acids mentioned in the specification and claims of the present invention those skilled in the art should understand that they actually include any one or both of the complementary double strands.
  • the nucleic acid sequence in the present application includes a DNA form or an RNA form, and disclosing one of them means that the other is also disclosed.
  • the present invention proposes an expression vector, the expression vector carries the aforementioned nucleic acid molecule.
  • the expression vector may include an optional control sequence, the control sequence is operably connected to the nucleic acid molecule.
  • the control sequence is one or more control sequences that can direct the expression of the nucleic acid molecule in a host.
  • the expression vector proposed in the embodiment of the present invention can efficiently express the antibody or antigen-binding fragment in a large amount in a suitable host cell.
  • operably connected means connecting the exogenous gene to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their intended function of regulating the transcription and translation of the exogenous gene.
  • control elements in the vector such as transcription control sequences and translation control sequences, etc.
  • the nucleic acid molecules can be directly or indirectly connected to the control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecules.
  • these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself.
  • nucleic acid molecules used to encode antibodies or antigen-binding fragments can be inserted into different vectors separately and independently, and it is common to insert them into the same vector.
  • Commonly used vectors can be, for example, plasmids, bacteriophages, etc.
  • Plasmid-X plasmid Plasmid-X plasmid.
  • the present invention proposes a method for preparing the above-mentioned antibody or antigen-binding fragment or bispecific antibody, comprising: introducing the above-mentioned expression vector into cells; culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment or bispecific antibody.
  • the method proposed according to some specific embodiments of the present invention can effectively obtain the antibody or antigen-binding fragment or bispecific antibody in large quantities in vitro.
  • the method for preparing the above-mentioned antibody or antigen-binding fragment or bispecific antibody may also include at least one of the following additional technical features:
  • the cells are not particularly limited, and either prokaryotic cells or eukaryotic cells can be used.
  • the cell is a eukaryotic cell.
  • the eukaryotic cell is a mammalian cell.
  • the expression efficiency of the recombinant antibody is higher.
  • the present invention provides a recombinant cell, wherein the recombinant cell contains the aforementioned nucleic acid, or expression vector, or is capable of expressing the aforementioned antibody or antigen-binding fragment or the bispecific antibody.
  • the recombinant cell is obtained by transfecting or transforming the expression vector.
  • the recombinant cell can efficiently and massively express the above-mentioned antibody or antigen-binding fragment or the bispecific antibody under appropriate conditions.
  • the recombinant cells of the present invention are not particularly limited and may be prokaryotic cells, eukaryotic cells or bacteriophages.
  • the prokaryotic cells may be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc.
  • the eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, insect cells such as armyworms, plant cells such as tobacco, mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc.
  • the recombinant cells of the present invention are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.
  • suitable conditions refer to conditions suitable for the expression of the antibody or antigen-binding fragment or double antibody described in this application. It is easy for those skilled in the art to understand that the conditions suitable for the expression of the antibody or antigen-binding fragment or double antibody include but are not limited to suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions” are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the antibody or antigen-binding fragment or double antibody according to the specific environment of the laboratory.
  • the present invention proposes an immunoconjugate, comprising the above-mentioned antibody or antigen-binding fragment or the bispecific antibody, and a therapeutic agent.
  • the antibody or antigen-binding fragment of the embodiment of the present invention can effectively bind to CD3 protein, and the bispecific antibody can bind to human or monkey CD3 protein and BCMA protein, or bind to human or monkey CD3 protein and B7H6 protein, effectively treating or preventing CD3 and BCMA, or CD3 and B7H6-mediated related diseases, therefore, the immunoconjugate containing the antibody or antigen-binding fragment can also bind to human or monkey CD3 protein, and the immunoconjugate containing the bispecific antibody can also bind to human or monkey CD3 protein and BCMA protein, or bind to human or monkey CD3 protein and B7H6 protein, and the immunoconjugate has good effects in preventing and/or treating CD3-mediated diseases, or CD3 and BCMA, or CD3 and B7H6-mediated related diseases
  • the present invention provides a composition comprising the above-mentioned antibody or antigen-binding fragment, bispecific antibody, nucleic acid molecule, expression vector
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD3 protein
  • the bispecific antibody can bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, and effectively inhibit the proliferation of tumor cells.
  • the composition containing the above substances can also effectively bind to human or monkey CD3 protein, or to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, and has good effects in preventing and/or treating CD3-mediated diseases, or CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the type of the composition is not particularly limited and can be a food composition or a pharmaceutical composition.
  • compositions of the invention may also be administered in combination with each other or with one or more other therapeutic compounds, for example, in combination with a chemotherapeutic agent.
  • the composition may also contain a chemotherapeutic agent.
  • the antibodies or antigen-binding fragments thereof, or immunoconjugates of the invention may also be combined with a second therapeutic agent, exemplary agents of which include, but are not limited to, other agents that inhibit CD3 activity (including other antibodies or antigen-binding fragments thereof, peptide inhibitors, small molecule antagonists, etc.) and/or agents that interfere with CD3 upstream or downstream signal transduction.
  • composition includes combinations separated in time and/or space, as long as they can work together to achieve the purpose of the present invention.
  • the components contained in the composition can be administered to the subject as a whole, or separately.
  • each component can be administered to the subject simultaneously or sequentially.
  • the present invention proposes a drug, including the above-mentioned antibody or antigen binding fragment, bispecific antibody, nucleic acid molecule, expression vector, recombinant cell or composition.
  • the antibody or antigen binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD3 protein, and the bispecific antibody can bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein.
  • a drug containing an effective amount of the antibody or antigen binding fragment or the active ingredient of the bispecific antibody or a series of substances thereof can also effectively bind to human or monkey CD3 protein, or to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, and has good effects in preventing and/or treating CD3-mediated diseases, or CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the above-mentioned medicine may further include at least one of the following additional technical features:
  • the drug may further include a pharmaceutically acceptable carrier.
  • the term "effective amount” or “effective dose” refers to an amount that can produce a function or activity on humans and/or animals and can be accepted by humans and/or animals.
  • the effective amount of the antibody or antigen-binding fragment or the bispecific antibody of the present invention may vary with the mode of administration and the severity of the disease to be treated.
  • the selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials).
  • the factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, depending on the urgency of the treatment situation, several divided doses may be administered daily, or the dose may be reduced proportionally.
  • pharmaceutically acceptable ingredients are suitable for use in humans and/or mammals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), i.e., substances with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
  • the medicine of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier.
  • Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof.
  • the drug preparation should match the mode of administration, wherein the mode of administration can be oral administration, nasal administration, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration or intraperitoneal administration, and the dosage form of the drug of the present invention is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent.
  • it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • the drug is preferably manufactured under sterile conditions.
  • the antibody or antigen-binding fragment or bispecific antibody can be administered by intravenous infusion or injection or intramuscular or subcutaneous injection.
  • anti-CD3 monoclonal antibody or bispecific antibody herein can also be prepared as a part of a kit or other diagnostic reagent as required.
  • the present invention proposes a kit, the kit containing the above-mentioned antibody or antigen-binding fragment thereof, bispecific antibody, nucleic acid molecule, expression vector or recombinant cell.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD3 protein
  • the bispecific antibody can bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein.
  • the kit containing the antibody or antigen-binding fragment can effectively detect human or monkey CD3 protein qualitatively or quantitatively
  • the kit containing the bispecific antibody can effectively detect human or monkey CD3 protein and BCMA protein, or human or monkey CD3 protein and B7H6 protein qualitatively or quantitatively.
  • the kit provided by the present invention can be used, for example, for immunoblotting, immunoprecipitation, etc., which involve the use of human or monkey CD3 and antibody specific binding properties for detection.
  • kits may contain any one or more of the following: antagonists, anti-CD3 antibodies or drug reference materials; protein purification columns; immunoglobulin affinity purification buffers; cell assay diluents; instructions or literature, etc.
  • Anti-CD3 antibodies can be used in different types of diagnostic tests, such as in vitro or in vivo detection of various diseases or the presence of drugs, toxins or other proteins.
  • the serum or blood of a subject can be tested to test for related diseases.
  • related diseases may include CD3-related diseases, such as cancer, wherein the cancer includes multiple myeloma, lymphoma, hemangioma, gastric cancer, At least one of liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • CD3-related diseases such as cancer, wherein the cancer includes multiple myeloma, lymphoma, hemangioma, gastric cancer, At least one of liver cancer, lung cancer, breast cancer, colorectal cancer, nasoph
  • the antibodies or antigen-binding fragments provided herein can also be used for radioimmunoassay and radioimmunotherapy of the above-mentioned diseases.
  • the dual antibodies are also applicable and will not be repeated here.
  • the kit may also include conventional reagents for detecting CD3, or CD3 and BCMA, or CD3 and B7H6, such as coating fluid, etc.
  • the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment thereof, nucleic acid molecule, expression vector, recombinant cell or composition in the preparation of a drug, and the drug is used to prevent and/or treat CD3-mediated related diseases.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD3 protein, and therefore, a drug containing an effective amount of the antibody or antigen-binding fragment or a series of substances thereof can also effectively bind to human or monkey CD3 protein, and has a good effect of preventing and/or treating CD3-mediated related diseases.
  • the above-mentioned use of preparing a medicine may also include at least one of the following additional technical features:
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the present invention proposes the use of the aforementioned bispecific antibodies, nucleic acid molecules, expression vectors, recombinant cells or compositions in the preparation of drugs, which are used to prevent and/or treat CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the bispecific antibodies of some specific embodiments of the present invention can bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, therefore, drugs containing an effective amount of the active ingredients of the bispecific antibodies or a series of substances thereof can also effectively bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, and have good effects in preventing and/or treating CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the above-mentioned use of preparing a medicine may also include at least one of the following additional technical features:
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment, nucleic acid molecule, expression vector or recombinant cell in preparing a kit for detecting CD3.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD3 protein and block the binding of the CD3 protein to its receptor. Therefore, the antibody or antigen-binding fragment can be used to prepare a kit for detecting CD3 protein, and the kit can effectively perform qualitative or quantitative detection of human or monkey CD3 protein.
  • the present invention proposes the use of the aforementioned bispecific antibodies, nucleic acid molecules, expression vectors or recombinant cells in the preparation of a kit for detecting CD3 and/or BCMA, or CD3 and/or B7H6.
  • the bispecific antibodies of some specific embodiments of the present invention can effectively bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, therefore, the bispecific antibodies can be used to prepare a kit for detecting CD3 and/or BCMA, or CD3 and/or B7H6, and the kit can effectively perform qualitative or quantitative detection of human or monkey CD3 and/or BCMA, or CD3 and/or B7H6.
  • the present invention proposes a method for treating or preventing CD3, or CD3 and BCMA, or CD3 and B7H6-mediated related diseases.
  • the method comprises administering to a subject at least one of the following: 1) the antibody or antigen binding fragment described above; 2) the bispecific antibody described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; 5) the recombinant cell described above; 6) the composition described above; and 7) the drug described above.
  • the bispecific antibody can effectively bind to human or monkey CD3 protein and BCMA protein, or to human or monkey CD3 protein and B7H6 protein, and the antibody or antigen binding fragment can bind to human or monkey CD3 protein, and can effectively treat or prevent CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases, such as autoimmune diseases or cancer. Therefore, the method according to an embodiment of the present invention can effectively treat or prevent CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases, preferably autoimmune diseases or cancer.
  • the above method for treating or preventing a disease may further include at least one of the following additional technical features:
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic hemoglobin Patients with this disorder may also be diagnosed with leukoencephalitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, autoimmune thyroid disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis, and acute idiopathic polyneuritis.
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes a method for diagnosing CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases.
  • it includes using at least one of the following to detect CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested: 1) the antibody or antigen binding fragment described above; 2) the bispecific antibody described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; and 5) the recombinant cell described above, based on the detection result of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6, the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested is determined.
  • the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, or antibodies or antigen-binding fragments expressed by recombinant cells proposed in the present application can effectively bind to human or monkey CD3 protein, and the bispecific antibodies, or nucleic acid molecules, expression vectors, or bispecific antibodies expressed by recombinant cells can effectively bind to CD3, or CD3 and/or BCMA, or CD3 and/or B7H6. Therefore, the method described in the present application can effectively detect the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample derived from the test individual, and can effectively diagnose related diseases caused by CD3, or CD3 and/or BCMA, or CD3 and/or B7H6.
  • the above method for diagnosing a disease may further include at least one of the following additional technical features:
  • the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample is not less than the minimum standard for disease, which indicates that the test sample is derived from a patient suffering from a disease related to CD3, or CD3 and/or BCMA, or CD3 and/or B7H6.
  • the value of the minimum standard can be determined by comparative analysis and verification of the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in a large number of individuals suffering from the disease related to CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 and a large number of healthy individuals.
  • the sample to be tested includes at least one of the following: blood, saliva, sweat, tissue, cell, blood, serum, plasma, feces and urine.
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes a method for staging CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases.
  • it includes using at least one of the following to detect CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested: 1) the antibody or antigen binding fragment described above; 2) the bispecific antibody described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; and 5) the recombinant cell described above, based on the detection result of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6, the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested is determined.
  • the bispecific antibodies proposed in the present application, or the bispecific antibodies expressed by nucleic acid molecules, expression vectors, and recombinant cells can effectively bind to human or monkey CD3 and/or BCMA, or CD3 and/or B7H6.
  • the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, and antibodies or antigen-binding fragments expressed by recombinant cells can effectively bind to human or monkey CD3 proteins.
  • the method described in the present application can effectively detect the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample from the subject, and evaluate the stage of related diseases caused by CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 based on the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6.
  • the above method for staging a disease may further include at least one of the following additional technical features:
  • the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample is not lower than the standard level of stage IV tumor, which indicates that the test sample is derived from a patient with stage IV tumor.
  • the content of CD3 and/or B7H6 being between the standard levels for tumor stage IV and stage III disease is an indication that the sample to be tested is derived from a patient with a tumor stage III; the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested is between the standard levels for tumor stage III and stage II disease, is an indication that the sample to be tested is derived from a patient with a tumor stage II; the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested is between the standard levels for tumor stage I and stage II disease, is an indication that the sample to be tested is derived from a patient with a tumor stage I.
  • the levels of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 when the tumor is at stage I, stage II, stage III, or stage IV vary depending on the type of tumor, and to determine the stage of the tumor, it is only necessary to compare the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample with the standard level of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 at the corresponding tumor stage, or to compare the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample with the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in a sample from an individual or group of individuals with a known stage of the disease.
  • the values of the standard levels of tumor stages I, II, III, and IV can be determined by comparative analysis and verification of the differences in the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in a large number of test samples from individuals suffering from the angiogenesis-related diseases and a large number of healthy individuals.
  • the sample to be tested includes at least one of the following: blood, saliva, sweat, tissue, cell, blood, serum, plasma, feces and urine.
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes a method for evaluating the prognosis of related diseases mediated by CD3, or CD3 and/or BCMA, or CD3 and/or B7H6.
  • it includes using at least one of the following to detect CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested: 1) the aforementioned double antibody; 2) the aforementioned antibody or antigen binding fragment; 3) the aforementioned nucleic acid molecule; 4) the aforementioned expression vector; and 5) the aforementioned recombinant cell, based on the detection result of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6, determine the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the sample to be tested.
  • CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 has an important influence on cancer.
  • the prognosis of such diseases can be effectively evaluated by monitoring the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in their tissues or excretions, such as peripheral blood, urine, etc.
  • the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the subject before and after treatment can be compared, or the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the subject after treatment can be compared with the CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 levels in normal individuals or diseased individuals, etc.
  • the bispecific antibodies proposed in the present application, or the bispecific antibodies expressed by nucleic acid molecules, expression vectors or recombinant cells can effectively bind to CD3 and/or BCMA, or CD3 and/or B7H6.
  • the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, antibodies or antigen-binding fragments expressed by recombinant cells can effectively bind to human or monkey CD3. Therefore, the method described in the present application can effectively detect the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample from the subject, and evaluate the prognosis of related diseases caused by CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 based on the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6.
  • the above method for evaluating disease prognosis may further include at least one of the following additional technical features:
  • the sample to be tested is derived from a patient suffering from a CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related disease before or after treatment.
  • the sample to be tested includes at least one of the following: blood, saliva, sweat, tissue, cell, blood, serum, plasma, feces and urine.
  • the prognostic effect of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases is determined based on the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample of a patient suffering from CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases before or after the treatment.
  • a decrease in the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in a test sample of a patient suffering from a CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related disease after treatment is an indication of a good prognosis for the patient.
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes the use of the aforementioned bispecific antibodies, antibodies or antigen-binding fragments, nucleic acid molecules, expression vectors, recombinant cells, compositions or drugs in the treatment or prevention of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases.
  • the bispecific antibodies have high binding activity with CD3 and/or BCMA, or CD3 and/or B7H6, and the antibodies or antigen-binding fragments can effectively bind to human or monkey CD3, and can effectively treat or prevent CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases.
  • the above-mentioned use may further include at least one of the following additional technical features:
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes the use of the aforementioned bispecific antibodies, antibodies or antigen-binding fragments, nucleic acid molecules, expression vectors or recombinant cells in diagnosing CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases, staging CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases, or evaluating the prognosis of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6-mediated related diseases.
  • the bispecific antibodies proposed in the present application or the bispecific antibodies expressed by nucleic acid molecules, expression vectors or recombinant cells can effectively bind to CD3 and/or BCMA, or CD3 and/or B7H6, and the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, antibodies or antigen-binding fragments expressed by recombinant cells can effectively bind to human or monkey CD3.
  • the method described in the present application can effectively detect the content of CD3, or CD3 and/or BCMA, or CD3 and/or B7H6 in the test sample derived from the subject, and can effectively diagnose, stage and evaluate the prognosis of related diseases mediated by CD3, or CD3 and/or BCMA, or CD3 and/or B7H6.
  • the above-mentioned use may further include at least one of the following additional technical features:
  • the CD3-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD3 and BCMA, or CD3 and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: multiple myeloma, lymphoma, hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colorectal cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, astrocytoma, neuroblastoma and glioma.
  • the "subject” or “individual” referred to in the present invention generally refers to a mammal, such as a primate and/or a rodent, in particular a human, a monkey or a mouse.
  • the mouse anti-CD3 monoclonal antibody obtained in the present invention has higher CD3 protein binding activity than the existing CD3 monoclonal antibody, and the CD3 protein includes human CD3 protein and monkey CD3 protein.
  • the humanized antibody obtained by humanizing the mouse anti-CD3 monoclonal antibody also has higher CD3 protein binding activity than the existing CD3 monoclonal antibody, the CD3 protein includes human CD3 protein and monkey CD3 protein, and the humanized antibody has lower immunogenicity and higher safety, The effect is longer lasting.
  • FIG1A is a graph showing the ELISA test results of different concentrations of mouse CD3 antibody (m47B5) binding to human CD3EG protein according to an embodiment of the present invention
  • FIG1B is a diagram showing the ELISA test results of different concentrations of mouse CD3 antibodies binding to human CD3ED protein according to an embodiment of the present invention.
  • FIG1C is a diagram showing the ELISA test results of different concentrations of mouse CD3 antibodies binding to monkey CD3EG protein according to an embodiment of the present invention.
  • FIG1D is a graph showing the ELISA test results of different concentrations of mouse CD3 antibodies binding to monkey CD3ED protein according to an embodiment of the present invention.
  • FIG2A is a graph showing the detection results of different concentrations of human-mouse chimeric CD3 antibody ch47B5 binding to human PBMC cells according to an embodiment of the present invention
  • 2B is a graph showing the detection results of different concentrations of human-mouse chimeric CD3 antibody ch47B5 binding to monkey PBMC cells according to an embodiment of the present invention
  • FIG3A is a graph showing the detection results of humanized CD3 antibodies of different concentrations binding to human CD3 protein according to an embodiment of the present invention.
  • FIG3B is a graph showing the detection results of humanized CD3 antibodies of different concentrations binding to monkey CD3 protein according to an embodiment of the present invention.
  • FIG4A is a graph showing the detection results of CD3 ⁇ BCMA bispecific antibodies of different concentrations binding to human CD3 protein according to an embodiment of the present invention.
  • FIG4B is a graph showing the detection results of CD3 ⁇ BCMA bispecific antibodies of different concentrations binding to human BCMA protein according to an embodiment of the present invention.
  • FIG5 is a graph showing the killing test results of NCI-H929 cells by CD3 ⁇ BCMA bispecific antibodies of different concentrations according to an embodiment of the present invention.
  • FIG6A is a graph showing the detection results of CD3 ⁇ B7H6 bispecific antibodies of different concentrations binding to human CD3 protein according to an embodiment of the present invention.
  • FIG6B is a graph showing the detection results of different concentrations of CD3 ⁇ BCMA bispecific antibodies binding to human B7H6 protein according to an embodiment of the present invention.
  • FIG. 7 is a graph showing the killing test results of HCT-15 cells by CD3 ⁇ BCMA bispecific antibodies of different concentrations according to an embodiment of the present invention.
  • first and second are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as “first” and “second” may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality” is two or more.
  • any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values.
  • the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be regarded as specifically disclosed in this article.
  • the antibody or antigen-binding fragment of the present invention is usually prepared by a biosynthetic method.
  • a person skilled in the art can easily prepare the encoding nucleic acid of the present invention by various known methods. These methods include but are not limited to: PCR, DNA artificial synthesis, etc. For specific methods, please refer to J. Sambrook, "Molecular Cloning Laboratory Guide”.
  • the encoding nucleic acid sequence of the present invention can be constructed by synthesizing the nucleotide sequence in segments and then performing overlap extension PCR. Wherein, the antibody or antigen fragment is numbered and defined using the Kabat numbering system.
  • the term "monoclonal antibody” refers to an antibody that has a single antigen binding site.
  • double antibody refers to an antibody having two different antigen binding sites.
  • mutant or “variant” may refer to any naturally occurring or engineered molecule comprising one or more nucleotide or amino acid mutations.
  • CDR complementarity determining region
  • CDR sequence refers to the amino acid sequence in an antibody that is responsible for antigen binding, for example, generally including: amino acid residues around 23-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable region, and around 31-35B (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Health Service, National Institutes of Health, Bethesda, MD.
  • hypovariable loops e.g., amino acid residues around 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable region, and 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable region (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
  • the term "identity" is used to describe an amino acid sequence or a nucleic acid sequence relative to a reference sequence, and the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences is determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research Foundation, Washington, DC). There are many algorithms for aligning sequences and determining sequence identity, including the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol.
  • GAP Genetics Computing Group
  • those skilled in the art can replace, add and/or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present invention to obtain variants of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region.
  • the variant sequence of the present invention can have at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% consistency (or homology) with the reference sequence.
  • the sequence consistency of the present invention can be measured using sequence analysis software.
  • the computer program BLAST with default parameters is used, especially BLASTP or TBLASTN.
  • the amino acid sequences described in the present invention are all shown in an N-terminal to C-terminal manner.
  • the monoclonal antibody of the present invention can be a full-length antibody or can only contain its functional fragments, or can be modified to affect function.
  • the present invention includes anti-CD3 antibodies with modified glycosylation patterns. In some applications, it can be useful to modify to remove undesirable glycosylation sites, or antibodies in which fucose moieties are not present on the oligosaccharide chains to, for example, enhance antibody-dependent cellular cytotoxicity (ADCC) function. In other applications, galactosylation modification can be performed to alter complement-dependent cytotoxicity (CDC).
  • the “full-length antibody” refers to a tetrapeptide chain structure composed of two identical light chains and two identical heavy chains connected by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD) or immunoglobulin E (IgE).
  • the term "functional fragment” as used herein refers in particular to antibody fragments such as CDR-grafted antibodies, Fab, F(ab')2, Fv or scFv, nanobodies, or any fragments that should be able to increase half-life by chemical modification, such as the addition of poly(alkylene) glycols, such as polyethylene glycol (“PEGylation, PEGylation”) (called Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG or Fab'-PEG PEGylated fragments) (“PEG” is polyethylene glycol), or by incorporation into liposomes, wherein the fragment has CD3 binding activity.
  • poly(alkylene) glycols such as polyethylene glycol (“PEGylation, PEGylation")
  • PEG
  • the functional fragment will be composed of or contain a partial sequence of the heavy chain variable region or light chain variable region of the antibody from which it is derived, and the partial sequence is sufficient to retain the same binding specificity and sufficient affinity as the antibody from which it is derived, preferably at least 1/100 of the affinity of the antibody from which it is derived, and at least 1/10 in a more preferred manner.
  • Such functional fragments will contain a minimum of 3 amino acids, and preferably 5, 10, 15, 25, 50 and 100 consecutive amino acids of the antibody sequence from which they are derived.
  • antigen-binding fragment used generally refers to an antigen-binding antibody fragment, which may include a portion of a complete antibody, generally an antigen-binding region or a variable region, such as, for example, CDR-grafted antibodies, Fab, Fab', F(ab')2, Fv or scFv, nanobodies, etc.
  • CDR transplanted antibody refers to transplanting the CDR of a monoclonal antibody of one species to the variable region of an antibody of another species.
  • the CDR of a mouse monoclonal antibody can be transplanted to the variable region of a human antibody to replace the human antibody CDR, so that the human antibody obtains the antigen binding specificity of the mouse monoclonal antibody while reducing its heterology.
  • Fab antibody generally refers to an antibody containing only Fab molecules, which are composed of VH and CH1 of the heavy chain and a complete light chain, with the light chain and the heavy chain connected by a disulfide bond.
  • F(ab') 2 antibody or “F(ab') 2” has two antigen-binding F(ab) portions linked together by disulfide bonds.
  • the term “nanoantibody” single domain antibody or VHH antibody
  • VHH antibody single domain antibody
  • a “heavy chain antibody” i.e., “antibody lacking light chains”
  • VH heavy chain variable region
  • CH2 and CH3 regions which specifically bind to the antigen through the heavy chain variable region.
  • Fv antibody generally refers to an antibody consisting only of a light chain variable region (VL) and a heavy chain variable region (VH) linked by non-covalent bonds, and is the smallest functional fragment of an antibody that retains a complete antigen binding site.
  • single-chain antibody or “scFv” refers to a fragment consisting of the variable regions of the heavy and light chains of an antibody connected by a short peptide.
  • the "knob into hole structure” refers to a knob (knob) and a hole (hole) mutation formed in the CH3 region of the antibody heavy chain constant region to facilitate the heavy chain to bite and form a heterodimer.
  • it is achieved by mutating the amino acids in the CH3 domain of the human IgG1 heavy chain constant region (T366S, L368A, Y407V, Y349C mutations in one chain, i.e., "hole”; T366W, S354C mutations in the other chain, i.e., "knob”).
  • the amino acid numbering here is based on the Kabat numbering.
  • T366S means that the T amino acid at position 366 according to the Kabat numbering system is replaced by the S amino acid.
  • anti-human CD3 monoclonal antibodies were produced by immunizing mice.
  • the experimental mice were C57BL/6, female, 6 weeks old (Jiangsu Jicui Yaokang Biotechnology Co., Ltd.), and the immunization antigens were human CD3E&D, human CD3E&G, monkey CD3E&D, and monkey CD3E&G extracellular segment protein (ACRO).
  • the complete adjuvant (Sigma, F5881) was mixed with the antigen and then intraperitoneally immunized. Each mouse was intraperitoneally injected with 100 ⁇ g.
  • the Ribi adjuvant system (Sigma, S6322) was mixed with the antigen for subsequent immunization.
  • immunization was performed every 2 weeks, for a total of 3 immunizations.
  • the serum of the immunized mice was taken for antibody titer ELISA detection, and the operation method was the conventional method in the art.
  • mice with high antibody titer in serum were selected for spleen cell fusion.
  • the selected mice were sprint immunized 72 hours before fusion, and a mixture of Ribi adjuvant system and the above antigens was intraperitoneally injected.
  • the spleen lymphocytes were fused with myeloma cells Sp2/0 cells (ATCC, CRL-8287) using an optimized PEG-mediated fusion step to obtain hybridoma cells.
  • the fused hybridoma cells were resuspended in HAT complete medium (RPMI-1640 medium containing 20% FBS, 1 ⁇ HAT and 1 ⁇ OPI), distributed in 96-well cell culture plates, and incubated at 37°C and 5% CO 2.
  • HAT complete medium was added on the 5th day after fusion, 50 ⁇ L/well. On the 7th to 8th day after fusion, according to the cell growth density, the medium was completely replaced, and the culture medium was HT complete medium (RPMI-1640 medium containing 20% FBS, 1 ⁇ HT and 1 ⁇ OPI), 200 ⁇ L/well.
  • HT complete medium RPMI-1640 medium containing 20% FBS, 1 ⁇ HT and 1 ⁇ OPI
  • the ELISA experiment was used to detect the binding properties of the mouse CD3 antibody m47B5 obtained in Example 1.
  • Human CD3ED protein ACRO biosystems, CDD-H52W1
  • human CD3EG protein ACRO biosystems, CDG-H52W5
  • monkey CD3ED protein ACRO biosystems, CDD-C52W4
  • monkey CD3EG protein ACRO biosystems, CDG-H52W6
  • coating buffer 35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6
  • the plate was washed three times with PBST (0.05% Tween 20-PBS, pH 7.2).
  • 300 ⁇ L of blocking buffer 1% BSA, 0.05% Tween20-PBS, pH 7.2
  • mouse antibody m47B5 was added to each well and incubate at room temperature for 1 hour.
  • wash 3 times with PBST Add 100 ⁇ L of HRP-sheep anti-mouse IgG secondary antibody (boster, item number BA1051) diluted with blocking buffer to each well and incubate at room temperature for 1 hour.
  • Figure 1A shows that the mouse m47B5 antibody of the present invention can bind to human CD3EG
  • Figure 1B shows that the mouse m47B5 antibody of the present invention can also bind to human CD3ED
  • Figure 1C shows that the mouse m47B5 antibody of the present invention can bind to monkey CD3EG
  • Figure 1D shows that the mouse m47B5 antibody of the present invention can bind to monkey CD3ED.
  • the total number of candidate hybridoma cells of the m47B5 antibody screened in implementation 1 and 2 was cultured to 10 6 , and the cells were collected by centrifugation at 800 rpm for 10 minutes, and the total RNA was extracted using a Trizol kit (Invitrogen); the total RNA was used as a template to synthesize a cDNA library (Invitrogen), and the cDNA was used as a template to PCR amplify the nucleic acid sequence of the variable region of the m47B5 antibody corresponding to the hybridoma cells.
  • the primer sequence used in the PCR amplification reaction is complementary to the first framework region or signal peptide region and constant region of the antibody variable region (for specific sequences, refer to Larrick, JW, et al., (1990) Scand. J. Immunol., 32, 121-128 and Coloma, JJ et al., (1991) BioTechniques, 11, 152-156).
  • PCR amplification was performed in a 50 ⁇ L reaction system, and 2 ⁇ L of cDNA, 5 ⁇ L of 10 ⁇ PCR buffer, 2 ⁇ L of upstream and downstream primers (5 ⁇ M), 2 ⁇ L of dNTP, 1 ⁇ L of Taq enzyme (Takara, Ex Taq), and 38 ⁇ L of H 2 O were added respectively; pre-denaturation at 95°C for 5 min, and temperature cycle was entered for PCR amplification.
  • the reaction conditions were: denaturation at 94°C for 30S, annealing at 58°C for 45S, extension at 72°C for 50S, a total of 32 cycles, and then extension at 72°C for 7 min.
  • the sequences of the heavy chain variable region (SEQ ID NO: 23) and light chain variable region (SEQ ID NO: 24) of mouse monoclonal antibody m47B5 were obtained.
  • the mouse monoclonal antibody m47B5 was used to construct a human-mouse chimeric antibody (ch47B5), wherein the heavy chain constant region of the chimeric antibody used was the heavy chain constant region of human IgG1.
  • PBMC peripheral blood mononuclear cells
  • monkey PBMC cells were diluted to 2 ⁇ 10 6 cells/mL with PBS, added to a 1.5mL EP tube at a volume of 100 ⁇ L/tube, and 10 ⁇ L/tube of goat serum was added thereto, and the cells were blocked at 4°C for 30min.
  • the above-mentioned human-mouse chimeric antibody ch47B5 was added with gradient concentrations (5-fold dilution, the highest final concentration was 10 ⁇ g/mL), and incubated at 4°C for 30min. 1mL PBS was added to the EP tube, centrifuged at 4°C, 3500rpm ⁇ 5min, the supernatant was discarded, and then washed with PBS.
  • the heavy chain or light chain variable region germline genes with high homology to the mouse monoclonal antibody m47B5 were selected as templates, and the CDRs of the mouse monoclonal antibody were transplanted into the corresponding human templates to form a variable region sequence in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
  • the amino acid residues were determined and annotated by the Kabat numbering system.
  • the heavy chain variable region sequence of the obtained humanized CD3 antibody h47B5 is shown in SEQ ID NO: 27, and the light chain variable region sequence is shown in SEQ ID NO: 28.
  • the nucleotide sequence encoding the heavy chain of the humanized antibody (SEQ ID NO: 43) and the nucleotide sequence encoding the light chain of the humanized antibody (SEQ ID NO: 44) were recombined into the pTT5 plasmid by molecular biology technology.
  • the pTT5 vector carrying the humanized anti-human CD3 antibody h47B5 light chain and heavy chain was used to transiently transfect ExpiCHO-S cells (Gibco, catalog number A29127) to prepare antibodies.
  • ExpiCHO-S cells The cell density of ExpiCHO-S cells was adjusted to (3-4) ⁇ 10 6 /mL and cultured overnight at 37°C, 8% CO 2 , and 120 rpm shaking.
  • the cells grow to 7 ⁇ 10 6 ⁇ 1 ⁇ 10 7 /mL and the viability is greater than 95%, they are ready for transfection.
  • Use fresh preheated ExpiCHO medium Gibco, Catalog No.
  • A2910002 to dilute the cells to 6 ⁇ 10 6 /mL, and transfect the above pTT5 plasmid carrying the light and heavy chains of the humanized anti-human CD3 antibody h47B5 and ExpiFectamine CHO transfection reagent (Gibco, Catalog No. A29129) into ExpiCHO-S cells at a molar ratio of 2:1. Culture at 37°C, 8% CO 2 , 120rpm shaking. 18-22h after transfection, mix ExpiFectamine CHO Enhancer and ExpiCHO Feed and immediately add the transfected cells, mix, and culture at 32°C, 5% CO 2 , 120rpm shaking.
  • the chromatography column was equilibrated with a pH 7.2 phosphate buffer, the supernatant was passed through the affinity chromatography column, eluted with an elution buffer (100 mM citric acid, pH 2.7), and finally concentrated and replaced with a PBS buffer.
  • the purified antibody was identified by SDS-PAGE to have a purity of more than 95%, and finally a humanized m47B5 antibody (heavy chain as shown in SEQ ID NO: 39, light chain as shown in SEQ ID NO: 40) was obtained.
  • the affinity of the humanized h47B5 antibody to the human CD3 antigen was tested by BIACORE. The results are shown in Table 2. The obtained humanized antibody has a good affinity to the CD3 antigen.
  • Human CD3 antigen ACRO biosystems, CDD-H52W1
  • monkey CD3 antigen ACRO biosystems, CDD-C52W4
  • coating buffer 35mM NaHCO 3 , 15mM Na 2 CO 3 , pH 9.6
  • 100 ⁇ L was added to each well of the ELISA plate and incubated at 4°C overnight. After that, it was washed 3 times with PBST (0.05% Tween 20-PBS, pH7.2).
  • FIGS. 3A and 3B show that the humanized h47B5 antibody of the present invention can bind to human and monkey CD3 antigens.
  • Examples 1-6 Based on the experimental results of Examples 1-6, the inventors designed a bispecific antibody CD3 ⁇ BCMA, and tested the binding activity and cell killing ability of the bispecific antibody.
  • the antibody contains two monovalent units, one of which is in the form of anti-CD3 scFv-Fc, and its heavy chain and light chain variable region amino acid sequences are from the sequence of the humanized antibody h47B5 obtained in Example 6 of the present invention, and the other monovalent unit is in the form of anti-BCMA scFv-Fc (sequence from US009273141B2), and the bispecific antibody is named CD3 ⁇ BCMA.
  • the bispecific antibody contains two polypeptide chains, namely: a heavy chain containing a CD3 single-chain antibody scFv (SEQ ID NO: 51), and a heavy chain containing a BCMA single-chain antibody scFv (SEQ ID NO: 52), wherein the heavy chain constant regions of the two chains are from human antibody IgG1. Since the molecule has a special asymmetric structure, in order to reduce the generation of homodimers, different amino acid mutations are introduced in the constant regions of the two chains to form a knob-in-hole structure. At the same time, in order to prevent cross-linking activation caused by Fc ⁇ receptors, (L234A/L235A) mutations are also introduced in the heavy chain constant region.
  • the method for preparing the bispecific antibody refers to the method described in Example 6.2, and the bispecific antibody is prepared by combining the plasmid ratio (1:1 or other ratio) and undergoing one-step affinity purification, wherein the relevant sequence of the bispecific antibody CD3 ⁇ BCMA is shown in Table 3.
  • Human BCMA (ACRO biosystems, BCA-H522y) or human CD3 antigen (ACRO biosystems, CDD-H52W1) was diluted to 2 ⁇ g/mL with coating buffer (35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6), and 100 ⁇ L was added to each well of the ELISA plate and incubated at 4°C overnight. Afterwards, the plate was washed three times with PBST (0.05% Tween 20-PBS, pH 7.2). 300 ⁇ L of blocking buffer (1% BSA, 0.05% Tween20-PBS, pH 7.2) was added to the plate and allowed to stand at room temperature for 2 h. The plate was then washed three times with PBST.
  • coating buffer 35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6
  • NCI-H929 cells were labeled with CellTrace Violet (thermo, C34557) and the cell density was adjusted to 1 ⁇ 10 5 /mL.
  • the cell density of PBMC was adjusted to 1 ⁇ 10 6 /mL, and PBMC and labeled NCI-H929 cells were mixed at a ratio of 1:1 and added to a 96-well round bottom plate, and then the above-mentioned bispecific antibodies or human IgG antibodies (control group) with gradient concentrations were added and mixed evenly. After incubation at 37°C for 24 hours, the cells were transferred to a flow tube through a 200-mesh nylon mesh, and the cells were tested 10 minutes after adding 7AAD.
  • the killing efficiency was characterized by the ratio of CTV+7AAD+ cells.
  • the results in Figure 5 show that as the concentration of CD3 ⁇ BCMA bispecific antibodies increases, the killing efficiency of PBMC against NCI-H929 multiple myeloma cells gradually increases.
  • Examples 1-6 Based on the experimental results of Examples 1-6, the inventors designed a bispecific antibody CD3 ⁇ B7H6, and tested the binding activity and cell killing ability of the bispecific antibody.
  • the antibody contains two monovalent units, one of which is in the form of anti-CD3scFv-Fc, in which the light chain and heavy chain variable regions in CD3scFv are from the humanized sequence of Example 6 of the present invention, and the other monovalent unit is in the form of anti-B7H6scFv-Fc (the B7H6scFv sequence is from CN114395045A).
  • This bispecific antibody is named CD3 ⁇ B7H6.
  • the bispecific antibody contains two polypeptide chains, namely: a heavy chain containing a CD3 single-chain antibody scFv (SEQ ID NO: 51) and a heavy chain containing a B7H6 single-chain antibody scFv (SEQ ID NO: 53).
  • the method for preparing the bispecific antibody of CD3 ⁇ B7H6 refers to Example 6.2, and the CD3 ⁇ B7H6 bispecific antibody is prepared by combining the plasmid ratio (1:1 or other ratios) and undergoing one-step affinity purification.
  • the relevant sequence of the bispecific antibody CD3 ⁇ B7H6 is shown in Table 4.
  • Human B7H6 (ACRO biosystems, B76-H52H8) or human CD3 antigen (ACRO biosystems, CDD-H52W) was diluted to 2 ⁇ g/mL with coating buffer (35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6), and 100 ⁇ L was added to each well of the ELISA plate and incubated at 4°C overnight. Afterwards, the plate was washed three times with PBST (0.05% Tween 20-PBS, pH 7.2). 300 ⁇ L of blocking buffer (1% BSA, 0.05% Tween20-PBS, pH 7.2) was added to the plate and allowed to stand at room temperature for 2 h.
  • coating buffer 35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6
  • PBST 0.05% Tween 20-PBS, pH 7.2
  • 300 ⁇ L of blocking buffer (1% BSA, 0.05% Tween20-PBS, pH 7.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)

Abstract

L'invention concerne un anticorps anti-CD3 et une application de celui-ci. L'anticorps comprend des séquences CDR choisies parmi au moins l'une des séquences d'acides aminés suivantes ou des séquences d'acides aminés identiques à au moins 95 % à celles-ci : des séquences CDR de région variable de chaîne lourde : SEQ ID NO : 1-3 ; et des séquences CDR de région variable de chaîne légère : SEQ ID NO : 4-6.
PCT/CN2023/086578 2022-10-27 2023-04-06 Anticorps anti-cd3 et son application WO2024087521A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211327357.1 2022-10-27
CN202211327357.1A CN115611985A (zh) 2022-10-27 2022-10-27 抗cd3的抗体及其应用

Publications (1)

Publication Number Publication Date
WO2024087521A1 true WO2024087521A1 (fr) 2024-05-02

Family

ID=84875913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/086578 WO2024087521A1 (fr) 2022-10-27 2023-04-06 Anticorps anti-cd3 et son application

Country Status (2)

Country Link
CN (1) CN115611985A (fr)
WO (1) WO2024087521A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115611985A (zh) * 2022-10-27 2023-01-17 合肥天港免疫药物有限公司 抗cd3的抗体及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114395047A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395044A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 重组抗体及其应用
WO2022135536A1 (fr) * 2020-12-25 2022-06-30 江苏先声药业有限公司 Anticorps cd3 humanisé et son utilisation
US20220204630A1 (en) * 2019-05-30 2022-06-30 Sunshine Lake Pharma Co., Ltd. Anti-trka antibodies and uses thereof
WO2022170033A1 (fr) * 2021-02-04 2022-08-11 The Trustees Of Dartmouth College Car à base de ligands naturels modifiés : évolution dirigée du récepteur du stress nkp30
CN115611985A (zh) * 2022-10-27 2023-01-17 合肥天港免疫药物有限公司 抗cd3的抗体及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220204630A1 (en) * 2019-05-30 2022-06-30 Sunshine Lake Pharma Co., Ltd. Anti-trka antibodies and uses thereof
WO2022135536A1 (fr) * 2020-12-25 2022-06-30 江苏先声药业有限公司 Anticorps cd3 humanisé et son utilisation
WO2022170033A1 (fr) * 2021-02-04 2022-08-11 The Trustees Of Dartmouth College Car à base de ligands naturels modifiés : évolution dirigée du récepteur du stress nkp30
CN114395047A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 双特异性抗体及其应用
CN114395044A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 重组抗体及其应用
CN115611985A (zh) * 2022-10-27 2023-01-17 合肥天港免疫药物有限公司 抗cd3的抗体及其应用

Also Published As

Publication number Publication date
CN115611985A (zh) 2023-01-17

Similar Documents

Publication Publication Date Title
JP7287963B2 (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
TWI771361B (zh) 人程序性死亡受體pd-1的單株抗體及其片段
TWI726608B (zh) 抗pd-l1抗體及其作為治療及診斷之用途
US20220348661A1 (en) Cd3-targeting antibody, bispecific antibody and use thereof
DK2513147T3 (en) Hitherto UNKNOWN ANTAGONIST ANTIBODIES AND THEIR FAB FRAGMENTS AGAINST GPVI AND USES THEREOF
KR20160044063A (ko) 항-pd1 항체 및 이의 치료 및 진단 용도
TW201934581A (zh) 抗ｂ７－ｈ４抗體、其抗原結合片段及其醫藥用途
CN112830969B (zh) 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒
WO2020168555A1 (fr) Fragment de liaison à l'antigène cd3 et application de celui-ci
TW201302794A (zh) 人類組織因子抗體及其用途
KR20210124993A (ko) 항-pd-1 항체, 이의 항원-결합 단편 및 이의 약학적 용도
JP2020536581A (ja) Ｂｔｎ２に特異性を有する抗体及びその使用
US20240190989A1 (en) Anti-cea and anti-cd137 multispecific antibodies and methods of use
WO2024087521A1 (fr) Anticorps anti-cd3 et son application
TW202132351A (zh) 抗cd47/抗pd-l1抗體及其應用
TW202116812A (zh) 抗ｄｌｌ３嵌合抗原受體及其用途
CN114907479A (zh) 抗cd112r抗体及其用途
WO2023174405A1 (fr) Anticorps humanisé anti-claudin18.2 et son utilisation
WO2024087515A1 (fr) Anticorps anti-cd16a et son utilisation
WO2024094017A1 (fr) Anticorps bispécifique pour glypicane-3 et son utilisation
WO2022068891A1 (fr) Anticorps anti-pd-1, et procédé de préparation associé et application associée
WO2023036215A1 (fr) Molécule de liaison à un antigène bispécifique et son utilisation
TWI841790B (zh) 靶向cd3的抗體、雙特異性抗體及其用途
CN117924488A (zh) 阻断性cd40抗体及其应用
WO2024078558A1 (fr) Anticorps anti-cd100 et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23881118

Country of ref document: EP

Kind code of ref document: A1